Our Scientific Advisory Board

Dr Phil Ambery is a Global Clinical Head within the late Cardiovascular, Metabolic and Renal research group in AstraZeneca Gothenburg and a Consultant Physician with Cambridge University Hospitals. As well as being medically trained he holds an eMBA from University of Gothenburg. Over nearly 25 years Phil has led medical affairs and clinical development teams across multiple projects, first in GlaxoSmithKline and for the past 11 years in AstraZeneca. He has a particular interest in obesity and associated comorbidities and has developed both incretin agonists and SGLT-2 inhibitor combination products in recent times. A particular interest of Phil's is how changing the metabolic profile in patients with cell growth disorders can alter mTOR activation and how this can positively impact both complications of weight gain and cancer risk.